Novartis treatment for vision loss meets goals in study

February 27, 2015 4:31 PM

3 0

ZURICH (Reuters) - Swiss drugmaker Novartis said on Friday its treatment for a leading cause of age-related blindness had met its primary goals in a study and could potentially pave the way for less frequent dosing compared to a drug already on the market.

Developed by Novartis's eyecare unit Alcon, the RTH258 drug is intended to treat wet age-related macular degeneration (AMD), which causes severe loss of vision in the over 50s and occurs when the center of the retina, or macula, deteriorates.

Read more

To category page

Loading...